Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.59 |
| ▸ | OXTR | P30559 | 13/20 | 0.56 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129595 | 0.92 | AVPR1A (0.49) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2131487 | 0.92 | AVPR1A (0.59) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2131571 | 0.92 | AVPR1A (0.70) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2129466 | 0.92 | AVPR1A (0.51) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2130144 | 0.92 | AVPR1A (0.59) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2629005 | 0.92 | AVPR1A (0.62) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2129088 | 0.90 | AVPR1A (0.57) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4828815 | 0.90 | AVPR1A (0.69) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL5552025 | 0.90 | AVPR1A (0.63) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18917251 | 0.90 | AVPR1A (0.57) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | claimed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | claimed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | claimed |
| EP-1632494-A1 | Vasopressin v1a antagonists | FERRING B.V. (NL) | 2006-03-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 8/4885AVPR2 2/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 8/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.